News

Dotinore, an ideal uric acid-lowering drug should be characterized by high efficiency in lowering uric acid, low impact on liver and kidney function, and clear mechanism of action. Dotinore, with its precise mechanism of action, can not only efficiently reduce blood uric acid levels, but also has unique advantages for patients with renal impairment. So, how does it become the “precision sniper” in the uric acid lowering field? And why is it regarded as the best choice for patients with gout combined with renal impairment? Let's find out!

Although HUA is associated with the progression of CKD, research advances in reducing CKD through uric acid-lowering therapy have been controversial. A study investigated the effect of dortinolide on renal function in patients with severe renal insufficiency by retrospectively analyzing data from 53 outpatients with HUA who were newly treated with dortinolide between December 2020 and October 2022. The results found that serum uric acid levels decreased significantly in all groups. 

Ilaprazole raw materials and enteric-coated tablets were developed by Korea's Yuhan Corporation in 2001, and the domestic Lizhu Group introduced the compound technology from this company in 2002, subsequently applying for research and development. It was approved for market release in December 2007 under the brand name Yilian, marking its global debut and being the only product in the domestic market.

Peptic ulcer disease is a common chronic condition of the Digestive System, characterized by ease of diagnosis and treatment, but also a tendency for recurrence. There are various treatment options available, including antacids, gastric mucosal protectants, H2 receptor antagonists, proton pump inhibitors (PPIs), and traditional Chinese medicine. Among these, PPIs are currently the most potent acid suppressants, with the best clinical efficacy and the widest application, holding over 90% of the market share.

Influenza is a global public health issue, causing a large number of infections and even deaths each year. Oseltamivir phosphate, as a special-effect drug for the treatment and prevention of influenza, has a huge market demand and broad development prospects. The frequent occurrence of public health events has further expanded the anti-influenza drug market.

Oseltamivir phosphate is an anti-influenza virus medication that belongs to the class of neuraminidase inhibitors. It effectively inhibits the replication and transmission of influenza viruses. By suppressing the activity of neuraminidase in influenza viruses, it prevents the release of viruses from infected cells, thereby reducing the spread of viruses within the body.

As an industry leader, HRD Pharm invested 250 million RMB to build a national chemical factory covering an area of about 60 acres, with 6 GMP standard production workshops and an independent R&D team of 50 people. 

High standards, high-quality outcomes is the cornerstone of HRD Pharm’s operations. The company strictly adheres to international standards and regulatory requirements, ensuring that every product that leaves its facilities is of the highest quality.